903 related articles for article (PubMed ID: 19748965)
21. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.
Vander Cruyssen B; Van Looy S; Wyns B; Westhovens R; Durez P; Van den Bosch F; Mielants H; De Clerck L; Peretz A; Malaise M; Verbruggen L; Vastesaeger N; Geldhof A; Boullart L; De Keyser F
Arthritis Res Ther; 2006; 8(4):R112. PubMed ID: 16978395
[TBL] [Abstract][Full Text] [Related]
22. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.
Ostendorf B; Iking-Konert C; Kurz K; Jung G; Sander O; Schneider M
Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502
[TBL] [Abstract][Full Text] [Related]
23. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
Marks SD; Patey S; Brogan PA; Hasson N; Pilkington C; Woo P; Tullus K
Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
[TBL] [Abstract][Full Text] [Related]
24. Infliximab in the treatment of refractory posterior uveitis.
Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ
Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
Illei GG; Yarboro CH; Kuroiwa T; Schlimgen R; Austin HA; Tisdale JF; Chitkara P; Fleisher T; Klippel JH; Balow JE; Boumpas DT
Rheumatology (Oxford); 2007 Jun; 46(6):952-6. PubMed ID: 17317716
[TBL] [Abstract][Full Text] [Related]
28. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection.
Wilson LE; Widman D; Dikman SH; Gorevic PD
Semin Arthritis Rheum; 2002 Dec; 32(3):163-73. PubMed ID: 12528081
[TBL] [Abstract][Full Text] [Related]
29. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P
Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577
[TBL] [Abstract][Full Text] [Related]
30. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
[TBL] [Abstract][Full Text] [Related]
31. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
Van Den Bosch F; Kruithof E; Baeten D; Herssens A; de Keyser F; Mielants H; Veys EM
Arthritis Rheum; 2002 Mar; 46(3):755-65. PubMed ID: 11920412
[TBL] [Abstract][Full Text] [Related]
32. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
Petri M; Jones RJ; Brodsky RA
Arthritis Rheum; 2003 Jan; 48(1):166-73. PubMed ID: 12528116
[TBL] [Abstract][Full Text] [Related]
33. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
Kalb RE; Gurske J
J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
[TBL] [Abstract][Full Text] [Related]
34. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
Grootscholten C; Snoek FJ; Bijl M; van Houwelingen HC; Derksen RH; Berden JH;
J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
[TBL] [Abstract][Full Text] [Related]
35. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
Yee CS; Gordon C; Dostal C; Petera P; Dadoniene J; Griffiths B; Rozman B; Isenberg DA; Sturfelt G; Nived O; Turney JH; Venalis A; Adu D; Smolen JS; Emery P
Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
[TBL] [Abstract][Full Text] [Related]
36. Rituximab therapy for childhood-onset systemic lupus erythematosus.
Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
[TBL] [Abstract][Full Text] [Related]
37. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
38. The use of infliximab in academic rheumatology practice: an audit of early clinical experience.
Fitzcharles MA; Clayton D; Ménard HA
J Rheumatol; 2002 Dec; 29(12):2525-30. PubMed ID: 12465146
[TBL] [Abstract][Full Text] [Related]
39. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
Sieper J; Baraliakos X; Listing J; Brandt J; Haibel H; Rudwaleit M; Braun J
Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
